CLCS Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -- compared to Cell Source, Inc.'s net margin of --. Cell Source, Inc.'s return on equity of -- beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Cell Source, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $80.00 which suggests that it could grow by 1455.43%. Given that Atossa Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Cell Source, Inc..

Cell Source, Inc. has a beta of -225.097, which suggesting that the stock is 22609.671% less volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 1.364, suggesting its more volatile than the S&P 500 by 36.379%.

Cell Source, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cell Source, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cell Source, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Cell Source, Inc.'s net income of -$1.4M is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Cell Source, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cell Source, Inc. is -- versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -- compared to Cell Source, Inc.'s net margin of -7753.43%. Cell Source, Inc.'s return on equity of -- beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Cell Source, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.36 which suggests that it could grow by 126.67%. Given that Celldex Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Celldex Therapeutics, Inc. is more attractive than Cell Source, Inc..

Cell Source, Inc. has a beta of -225.097, which suggesting that the stock is 22609.671% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.242, suggesting its more volatile than the S&P 500 by 24.184%.

Cell Source, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cell Source, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cell Source, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Cell Source, Inc.'s net income of -$1.4M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Cell Source, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cell Source, Inc. is -- versus 601.06x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -- compared to Cell Source, Inc.'s net margin of 84.08%. Cell Source, Inc.'s return on equity of -- beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Cell Source, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 433.98%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Cell Source, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Cell Source, Inc..

Cell Source, Inc. has a beta of -225.097, which suggesting that the stock is 22609.671% less volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.819, suggesting its less volatile than the S&P 500 by 181.948%.

Cell Source, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cell Source, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cell Source, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Cell Source, Inc.'s net income of -$1.4M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Cell Source, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cell Source, Inc. is -- versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Cell Source, Inc.'s net margin of -316.61%. Cell Source, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Cell Source, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Cell Source, Inc..

Cell Source, Inc. has a beta of -225.097, which suggesting that the stock is 22609.671% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Cell Source, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cell Source, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cell Source, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Cell Source, Inc.'s net income of -$1.4M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Cell Source, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cell Source, Inc. is -- versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.